The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
β-Amyloid Fragment 25–35 Causes Mitochondrial Dysfunction in Primary Cortical Neurons
Open accessAbstract
β-Amyloid deposition and compromised energy metabolism both occur in vulnerable brain regions in Alzheimer's disease. It is not known whether β-amyloid is the cause of impairment of energy metabolism, nor whether impaired energy metabolism is specific to neurons. Our results, using primary neuronal cultures, show that 24-h incubation with Aβ25–35 caused a generalized decrease in the specific activity of mitochondrial enzymes per milligram of cellular protein, induced mitochondrial swelling, and decreased total mitochondrial number. Incubation with Aβ25–35 decreased ATP concentration to 58% of control in neurons and 71% of control in astrocytes. Levels of reduced glutathione were also lowered by Aβ25–35 in both neurons (from 5.1 to 2.9 nmol/mg protein) and astrocytes (from 25.2 to 14.9 nmol/mg protein). We conclude that 24-h treatment with extracellular Aβ25–35 causes mitochondrial dysfunction in both astrocytes and neurons, the latter being more seriously affected. In astrocytes mitochondrial impairment was confined to complex I inhibition, whereas in neurons a generalized loss of mitochondria was seen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 1×
“Consistent with previous reports (Yankner et al., 1990; Mattson et al., 1992), 24-h incubation with A 25–35 was toxic to neuronal cultures (Fig.”
ResultMitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 3×
“In particular, morphometry of biopsy brain tissue from AD patients and controls indicated a significant decrease in the number of intact mitochondria and an increase in lipofuscin, a marker of autophagic mitochondrial breakdown (Hirai et al., 2001).”
BackgroundPike, C. J., Walencewicz‐Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., & Cotman, C. W. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64010253.x · Cited by 699 · cited 2×
“A 25–35 has been used in a number of studies and found to have many effects in common with full length A 1–40/42 (Pike et al., 1995; Mark et al., 1997b; Pereira et al., 1999).”
BackgroundMethodMark, R. J., Pang, Z., Geddes, J. W., Uchida, K., & Mattson, M. P. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-03-01046.1997 · Cited by 551
Brain cytochrome oxidase in Alzheimer's disease
Kish, S. J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L., Wilson, J. M., DiStefano, L. M., & Nobrega, J. N. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09439.x · Cited by 537 · cited 1×
“There is evidence for a profound deficit of mitochondrial metabolism including reduced activity of the enzyme complexes cytochrome oxidase (Kish et al., 1992; Mutisya et al., 1994; Parker, Jr. et al., 1994), pyruvate dehydrogenase (PDHC) (Sorbi et al., 1983), and -ketoglutarate dehydrogenase (…”
BackgroundKeller, J. N., Pang, Z., Geddes, J. W., Begley, J. G., Germeyer, A., Waeg, G., & Mattson, M. P. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010273.x · Cited by 439 · cited 2×
“A has also been shown to induce HNE formation in synaptosomes at concentrations that also caused significant depletion of ATP (Keller et al., 1997).”
BackgroundMitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease
de la Monte, S. M., Luong, T., Neely, T. R., Robinson, D., & Wands, J. R. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780140 · Cited by 227
Functional mitochondria are required for amyloid β‐mediated neurotoxicity
Cardoso, S. M., Santos, S., Swerdlow, R. H., & Oliveira, C. R. (2001) · The FASEB Journal · doi:10.1096/fj.00-0561fje · Cited by 203 · cited 1×
“More recently, it was reported that functional mitochondria were required for A toxicity in NT2 cells (Cardoso et al., 2001), suggesting that A toxicity was mediated via effects on mitochondria.”
BackgroundPereira, C., Santos, M. S., & Oliveira, C. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0241 · Cited by 156
Cited by
Molecular pathways to neurodegeneration
Bossy-Wetzel, E., Schwarzenbacher, R., & Lipton, S. A. (2004) · Nature Medicine · doi:10.1038/nm1067 · Cited by 740
Abramov, A. Y., Canevari, L., & Duchen, M. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4042-03.2004 · Cited by 587
Self-citationChong, Z. Z., Li, F., & Maiese, K. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.004 · Cited by 536
Pich, S., Bach, D., Briones, P., Liesa, M., Camps, M., Testar, X., Palacín, M., & Zorzano, A. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi149 · Cited by 455
McManus, M. J., Murphy, M. P., & Franklin, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0552-11.2011 · Cited by 432
Mitophagy in neurodegeneration and aging
Fivenson, E. M., Lautrup, S., Sun, N., Scheibye-Knudsen, M., Stevnsner, T., Nilsen, H., Bohr, V. A., & Fang, E. F. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.02.007 · Cited by 364
Abramov, A. Y., Canevari, L., & Duchen, M. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05088.2003 · Cited by 337
Self-citationCopper-Dependent Inhibition of Human Cytochrome c Oxidase by a Dimeric Conformer of Amyloid-β1-42
Crouch, P. J., Blake, R., Duce, J. A., Ciccotosto, G. D., Li, Q.-X., Barnham, K. J., Curtain, C. C., Cherny, R. A., Cappai, R., Dyrks, T., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4276-04.2005 · Cited by 327
Mitochondria, calcium and cell death: A deadly triad in neurodegeneration
Celsi, F., Pizzo, P., Brini, M., Leo, S., Fotino, C., Pinton, P., & Rizzuto, R. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.02.021 · Cited by 323
Amyloid β-induced Changes in Nitric Oxide Production and Mitochondrial Activity Lead to Apoptosis
Keil, U., Bonert, A., Marques, C. A., Scherping, I., Weyermann, J., Strosznajder, J. B., Müller-Spahn, F., Haass, C., Czech, C., Pradier, L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405600200 · Cited by 287
Search for natural products related to regeneration of the neuronal network
Tohda, C., Kuboyama, T., & Komatsu, K. (2005) · Neurosignals · doi:10.1159/000085384 · Cited by 257
Diabetes and Alzheimer’s disease crosstalk
Baglietto-Vargas, D., Shi, J., Yaeger, D. M., Ager, R., & LaFerla, F. M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.005 · Cited by 256
Resende, R., Ferreiro, E., Pereira, C., & Resende de Oliveira, C. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.06.036 · Cited by 235
Oxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
The emerging role of glutathione in Alzheimer’s disease
Saharan, S., & Mandal, P. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132483 · Cited by 168
Reddy, P. H., Manczak, M., & Yin, X. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170051 · Cited by 116
Galea, E., Launay, N., Portero-Otin, M., Ruiz, M., Pamplona, R., Aubourg, P., Ferrer, I., & Pujol, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.005 · Cited by 108
Clementi, M. E., Pezzotti, M., Orsini, F., Sampaolese, B., Mezzogori, D., Grassi, C., Giardina, B., & Misiti, F. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.137 · Cited by 105
Astrocyte modulation of in vitro β‐amyloid neurotoxicity
Paradisi, S., Sacchetti, B., Balduzzi, M., Gaudi, S., & Malchiodi‐Albedi, F. (2004) · Glia · doi:10.1002/glia.20005 · Cited by 68
“Notably, glutathione cycle impairment has been described after 25–35 A peptide treatment (Casley et al., 2002; Cardoso and Oliveira, 2003).”
BackgroundRhein, V., & Eckert, A. (2007) · Archives of Physiology and Biochemistry · doi:10.1080/13813450701572288 · Cited by 56
Choi, S. J., Lee, J.-H., Heo, H. J., Cho, H. Y., Kim, H. K., Kim, C.-J., Kim, M. O., Suh, S. H., & Shin, D.-H. (2011) · Journal of Medicinal Food · doi:10.1089/jmf.2010.1452 · Cited by 57
Jeong, H. R., Jo, Y. N., Jeong, J. H., Kim, H. J., Kim, M.-J., & Heo, H. J. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2013.2881 · Cited by 26
Metadata
- Authors
- Casley, C. S., Land, J. M., Sharpe, M. A., Clark, J. B., Duchen, M. R., & Canevari, L.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 10
- Issue
- 3
- Pages
- 258-267
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2002239634
- Cited by
- 205
- References
- 9
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.